Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis

OBJECTIVE: Cerebrospinal fluid (CSF) biomarkers are shown to facilitate a risk identification of patients with mild cognitive impairment (MCI) into different risk levels of progression to Alzheimer’s disease (AD). Knowing a patient’s risk level provides an opportunity for earlier interventions, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaud, Tzeyu L., Kane, Robert L., McCarten, J. Riley, Gaugler, Joseph E., Nyman, John A., Kuntz, Karen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103924/
https://www.ncbi.nlm.nih.gov/pubmed/29623628
http://dx.doi.org/10.1007/s41669-017-0054-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103924/
https://www.ncbi.nlm.nih.gov/pubmed/29623628
http://dx.doi.org/10.1007/s41669-017-0054-z

Ejemplares similares